NM_014467.3(SRPX2):c.959C>T (p.Ala320Val) AND Rolandic epilepsy, intellectual disability, and speech dyspraxia, X-linked

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Aug 14, 2020
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001359446.7

Allele description [Variation Report for NM_014467.3(SRPX2):c.959C>T (p.Ala320Val)]

NM_014467.3(SRPX2):c.959C>T (p.Ala320Val)

Gene:

SRPX2:sushi repeat containing protein X-linked 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

Xq22.1

Genomic location:

Preferred name:

NM_014467.3(SRPX2):c.959C>T (p.Ala320Val)

HGVS:

NC_000023.11:g.100666931C>T
NG_021337.1:g.27766C>T
NM_014467.3:c.959C>TMANE SELECT
NP_055282.1:p.Ala320Val
NC_000023.10:g.99921928C>T

Protein change:

A320V

Links:

dbSNP: rs780126596

NCBI 1000 Genomes Browser:

rs780126596

Molecular consequence:

NM_014467.3:c.959C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Rolandic epilepsy, intellectual disability, and speech dyspraxia, X-linked (RESDX)
Synonyms:: Rolandic epilepsy, impaired intellectual development, and speech dyspraxia
Identifiers:: MONDO: MONDO:0010388; MedGen: C1845070; OMIM: 300643

Recent activity

Clear Turn Off Turn On

PREDICTED: Homo sapiens MOB kinase activator 2 (MOB2), transcript variant X9, mR...
PREDICTED: Homo sapiens MOB kinase activator 2 (MOB2), transcript variant X9, mRNA
gi|2462527825|ref|XM_054370056.1|

Nucleotide
PREDICTED: Homo sapiens MOB kinase activator 2 (MOB2), transcript variant X12, m...
PREDICTED: Homo sapiens MOB kinase activator 2 (MOB2), transcript variant X12, mRNA
gi|2462527831|ref|XM_054370059.1|

Nucleotide
PREDICTED: Mus musculus PNN interacting serine/arginine-rich (Pnisr), transcript...
PREDICTED: Mus musculus PNN interacting serine/arginine-rich (Pnisr), transcript variant X1, mRNA
gi|1907156870|ref|XM_006538184.5|

Nucleotide
Dleu2 deleted in lymphocytic leukemia, 2 [Mus musculus]
Dleu2 deleted in lymphocytic leukemia, 2 [Mus musculus]
Gene ID:668253

Gene
Pde6d phosphodiesterase 6D, cGMP-specific, rod, delta [Mus musculus]
Pde6d phosphodiesterase 6D, cGMP-specific, rod, delta [Mus musculus]
Gene ID:18582

Gene

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV001555317	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Aug 14, 2020)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV001555317

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Aug 14, 2020)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001555317.4

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SRPX2-related conditions. This variant is present in population databases (rs780126596, ExAC 0.07%). This sequence change replaces alanine with valine at codon 320 of the SRPX2 protein (p.Ala320Val). The alanine residue is weakly conserved and there is a small physicochemical difference between alanine and valine.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Oct 13, 2024

ClinVar

Relating variation to medicine